00:14 , Jul 16, 2019 |  BC Extra  |  Clinical News

July 15 Clinical Quick Takes: Zejula meets in Phase III for 1L ovarian cancer; plus Capricor, Avrobio and NIH

Zejula improves 1L ovarian cancer PFS  Zejula niraparib met the primary endpoint in the Phase III PRIMA trial to treat first-line ovarian cancer following platinum chemotherapy, significantly improving progression-free survival regardless of patients' biomarker status...
20:42 , Feb 8, 2019 |  BC Week In Review  |  Clinical News

Capricor resumes DMD trial, will seek funding

Capricor Therapeutics Inc. (NASDAQ:CAPR) resumed dosing in the Phase II HOPE-2 trial of IV CAP-1002 for Duchenne muscular dystrophy (DMD). In December, the company placed a hold on the trial to investigate a severe allergic...
01:55 , Jan 4, 2019 |  BC Week In Review  |  Clinical News

Capricor places DMD trial on hold

Capricor Therapeutics Inc. (NASDAQ:CAPR) placed a hold on the Phase II HOPE-2 trial of IV CAP-1002 for Duchenne muscular dystrophy (DMD) to investigate a severe allergic reaction that occurred in a patient during CAP-1002 infusion....
19:58 , Jan 19, 2018 |  BC Week In Review  |  Company News

Capricor and Cedars-Sinai expand cardiosphere deal

Cedars-Sinai Medical Center (Los Angeles, Calif.) granted cardiovascular company Capricor Therapeutics Inc. (NASDAQ:CAPR) exclusive, worldwide rights to develop and commercialize cardiosphere-derived cells (CDC) and CDC-derived extracellular vesicles, including exosomes, by adding seven new patent applications...
23:59 , Nov 9, 2017 |  BC Innovations  |  Targets & Mechanisms

Vesicular fuel

A study from Memorial Sloan Kettering Cancer Center has shown for the first time that fibroblasts can cause drug resistance by revving up the metabolism of dormant cancer cells. But the authors’ proposal that exosomes...
20:23 , Jul 28, 2017 |  BC Week In Review  |  Clinical News

FDA to allow limb function endpoint in Capricor's DMD trials

Capricor Therapeutics Inc. (NASDAQ:CAPR) said it received minutes from an FDA meeting indicating the agency’s “willingness to accept" the Performance of the Upper Limb (PUL) outcome measure as a BLA-supportive primary efficacy endpoint in trials...
00:10 , Jul 28, 2017 |  BC Extra  |  Clinical News

FDA to allow limb function endpoint in Capricor's DMD trials

Capricor Therapeutics Inc. (NASDAQ:CAPR) jumped $0.29 (29%) to $1.30 on Thursday after saying it received minutes from an FDA meeting indicating the agency’s “willingness to accept" the Performance of the Upper Limb (PUL) outcome measure...
23:17 , Jul 13, 2017 |  BC Week In Review  |  Company News

Janssen declines option to Capricor's CAP-1002, Capricor to start DMD trials

Capricor Therapeutics Inc. (NASDAQ:CAPR) said that the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) declined its option to develop and commercialize the biotech's CAP-1002 . Janssen had rights under a 2014 deal. Capricor...
21:00 , Jun 22, 2017 |  BC Innovations  |  Targets & Mechanisms

Exosomes deliver

Codiak BioSciences Inc. founder Raghu Kalluri has published the first animal data demonstrating exosomes can be used as drug delivery vehicles to treat cancer -- not just diagnose it. The findings also mark the unveiling...
00:17 , May 19, 2017 |  BC Week In Review  |  Clinical News

Capricor's CAP-1002 misses Phase I/II heart repair endpoint

Capricor Therapeutics Inc. (NASDAQ:CAPR) reported data from a 6-month interim futility analysis of the Phase I/II ALLSTAR trial in 142 patients with residual cardiac dysfunction following a myocardial infarction (MI) showing that intracoronary CAP-1002 was...